CSPC Pharmaceutical Profit Drops 10.3% After Missing Forecasts

Edgen Stock·Mar 25 2026, 04:49

Share to

Share to

Copy link

Key Takeaways

CSPC Pharmaceutical Group announced disappointing full-year 2025 results on March 25, with both revenue and net profit falling short of analyst expectations. The 10.3% decline in net profit signals potential operational headwinds and has raised concerns among investors about the company's growth trajectory.

Profit Decline: Net profit for 2025 fell 10.3% year-on-year to 3.88 billion RMB, well below the 4.87 billion RMB forecast.
Revenue Shortfall: Full-year revenue was 26.01 billion RMB, missing the consensus estimate of 27.82 billion RMB.
Shareholder Payout: Despite the earnings miss, the company declared a final dividend of 0.15 HKD per share.

Full-Year Profit Falls 10.3% on Weaker Revenue

CSPC Pharmaceutical Group (HKEX: 1093) reported a significant downturn in its financial performance for the full year 2025. In its announcement on March 25, the company disclosed that net profit contracted 10.3% year-on-year to 3.88 billion RMB. This figure fell approximately 20% short of the 4.87 billion RMB that analysts had estimated. The profit decline was driven by weaker-than-expected sales, with annual revenue coming in at 26.01 billion RMB, missing the market forecast of 27.82 billion RMB.

Earnings Miss Signals Potential Headwinds

The dual miss on both top-line revenue and bottom-line profit points to underlying operational or market challenges for the pharmaceutical giant. Such a wide deviation from estimates often triggers a negative market reaction, placing downward pressure on the company's stock price. The results raise questions about CSPC's profitability and competitive positioning. While the board declared a final dividend of 0.15 HKD per share, this payout may not be enough to counter investor concerns about the firm's near-term growth prospects.